Home / Resource Library / Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

ASH 2020: Results of a phase II study examined pembrolizumab combined with chemotherapy for treatment of relapsed Hodgkin lymphoma.